Alectinib for treatment of ALK-positive non-small-cell lung cancer.

about

Metabolites of alectinib in human: their identification and pharmacological activity.The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.

P2860

Q40991511-01502D9C-FD06-4171-8773-70F83D09DB5C Q51740588-E090CCD2-1D19-4E2C-A8C2-80AA96CA543D Q53191682-7E3B2F03-BEB0-49E6-A3EB-8B045D2DDC29

P2860

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q38805618

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

@en

type

Item

label

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

@en

prefLabel

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

@en

P1476

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

@en

P2093

Maurice Pérol

http://www.w3.org/2001/XMLSchema#string

Virginie Avrillon

http://www.w3.org/2001/XMLSchema#string

P2860

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

P304

321-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0386

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27780368

http://www.w3.org/2001/XMLSchema#string

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

about

P2860

P2860

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698